Mohamad El Moheb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mohamad El Moheb has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Kaelyn C. Cummins
Department of Surgery University of Virginia Charlottesville Virginia USA
11 shared publications - Allan Tsung
Department of Surgery, University of Virginia, Charlottesville, Virginia, USA
10 shared publications - Carolyn Tsung
Department of Surgery, University of Virginia, Charlottesville, Virginia
10 shared publications - Chengli Shen
Division of Surgical Sciences, Department of Surgery (R.T., Y.H., T.S., J.L., C.S., X.Z., J.M., K.C.K., L.-W.G.), School of Medicine, University of Virginia, Charlottesville
10 shared publications - David R. Brenin
Department of Surgery, University of Virginia, Charlottesville, Virginia
10 shared publications - Emily Pauline Rabinovich
Department of Surgery, University of Virginia Health System, Charlottesville, VA, USA
10 shared publications
Latest Publications
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Figure 2 shows posterior predictive checks for the model predicting PCS change from diagnosis to two years. The three panels compare observed versus replicated data in terms of overall distribution, mean, and variance to assess model fit.
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Figure 2 shows posterior predictive checks for the model predicting PCS change from diagnosis to two years. The three panels compare observed versus replicated data in terms of overall distribution, mean, and variance to assess model fit.
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Figure 1 shows violin plots with medians and interquartile ranges for baseline physical (PCS) and mental (MCS) component scores, before versus after diagnosis (Panel A), and at diagnosis versus two years later (Panel B).
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Figure 1 shows violin plots with medians and interquartile ranges for baseline physical (PCS) and mental (MCS) component scores, before versus after diagnosis (Panel A), and at diagnosis versus two years later (Panel B).
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Background:Evidence comparing patients’ health-related quality of life (HRQOL) before and after breast cancer diagnosis, and factors influencing these trajectories, is limited because of unpredictable onset. We analyzed predictors of HRQOL change in elderly patients with breast cancer across two transitions: pre- to post-diagnosis and at diagnosis versus 2 years later.Methods:Using Surveillance, Epidemiology, and End Results–Medicare Health Outcomes Survey linkage, we analyzed patients with breast cancer >65 years who completed two HRQOL surveys. Two cohorts were examined: patients with surveys before and within 1 year after diagnosis (cohort 1) and those with surveys within 1 year of diagnosis and 2 years after diagnosis (cohort 2). Bayesian regression identified predictors of physical component summary (PCS) and mental component summary (MCS) score changes.Results:In cohort 1 (n = 1,546), advanced stage was associated with greater HRQOL decline, with mean PCS changes ranging from −2.1 to −6.5 and MCS from −2.0 to −5.1. Baseline activities of daily living (ADL) limitations were associated with mean PCS declines ranging from −2.0 to −2.6 and mean MCS decline of −2.0. Better baseline health perception was protective with mean PCS increases ranging from +1.4 to +3.4. In cohort 2 (n = 891), baseline ADL limitations were associated with mean PCS declines ranging from −1.6 to −5.5 and mean MCS decline of −2.5, whereas poor health perception was associated with mean PCS decline of −3.2. Excellent health perception was protective (mean MCS: +4.1). Surgery, chemotherapy, and radiation had no HRQOL affect.Conclusions:Baseline health perception and ADL limitations are critical determinants of HRQOL trajectories, outweighing treatments.Impact:Early intervention strategies based on baseline assessments may improve survivorship.
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Background:Evidence comparing patients’ health-related quality of life (HRQOL) before and after breast cancer diagnosis, and factors influencing these trajectories, is limited because of unpredictable onset. We analyzed predictors of HRQOL change in elderly patients with breast cancer across two transitions: pre- to post-diagnosis and at diagnosis versus 2 years later.Methods:Using Surveillance, Epidemiology, and End Results–Medicare Health Outcomes Survey linkage, we analyzed patients with breast cancer >65 years who completed two HRQOL surveys. Two cohorts were examined: patients with surveys before and within 1 year after diagnosis (cohort 1) and those with surveys within 1 year of diagnosis and 2 years after diagnosis (cohort 2). Bayesian regression identified predictors of physical component summary (PCS) and mental component summary (MCS) score changes.Results:In cohort 1 (n = 1,546), advanced stage was associated with greater HRQOL decline, with mean PCS changes ranging from −2.1 to −6.5 and MCS from −2.0 to −5.1. Baseline activities of daily living (ADL) limitations were associated with mean PCS declines ranging from −2.0 to −2.6 and mean MCS decline of −2.0. Better baseline health perception was protective with mean PCS increases ranging from +1.4 to +3.4. In cohort 2 (n = 891), baseline ADL limitations were associated with mean PCS declines ranging from −1.6 to −5.5 and mean MCS decline of −2.5, whereas poor health perception was associated with mean PCS decline of −3.2. Excellent health perception was protective (mean MCS: +4.1). Surgery, chemotherapy, and radiation had no HRQOL affect.Conclusions:Baseline health perception and ADL limitations are critical determinants of HRQOL trajectories, outweighing treatments.Impact:Early intervention strategies based on baseline assessments may improve survivorship.
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table S2 presents the posterior estimates, 95% credible intervals, and probabilities of direction (PD) for each predictor in the Bayesian regression model evaluating the association between patient factors and changes in Mental Component Summary (MCS) scores between pre-diagnosis and diagnosis relative to the minimally clinically important difference (MCID) threshold.
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table S2 presents the posterior estimates, 95% credible intervals, and probabilities of direction (PD) for each predictor in the Bayesian regression model evaluating the association between patient factors and changes in Mental Component Summary (MCS) scores between pre-diagnosis and diagnosis relative to the minimally clinically important difference (MCID) threshold.
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table S4 compares demographic, socioeconomic, clinical, and health-related baseline characteristics between two groups of elderly breast cancer patients from the SEER-MHOS dataset: those who completed both pre- and post-diagnosis HRQOL surveys (n=1,546) and those who completed only a pre-diagnosis survey (n=1,416). Differences are presented as proportions or mean differences with corresponding 95% confidence intervals. The table highlights potential selection biases in survey completion and the representativeness of the longitudinal cohort
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table S4 compares demographic, socioeconomic, clinical, and health-related baseline characteristics between two groups of elderly breast cancer patients from the SEER-MHOS dataset: those who completed both pre- and post-diagnosis HRQOL surveys (n=1,546) and those who completed only a pre-diagnosis survey (n=1,416). Differences are presented as proportions or mean differences with corresponding 95% confidence intervals. The table highlights potential selection biases in survey completion and the representativeness of the longitudinal cohort
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table S5 compares the baseline demographic, clinical, and health-related characteristics of breast cancer patients who completed both the diagnosis and 2-year follow-up surveys versus those who only completed the diagnosis survey, highlighting potential selection bias in longitudinal HRQOL analysis.
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table S5 compares the baseline demographic, clinical, and health-related characteristics of breast cancer patients who completed both the diagnosis and 2-year follow-up surveys versus those who only completed the diagnosis survey, highlighting potential selection bias in longitudinal HRQOL analysis.
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table 3 presents the R-hat convergence diagnostics for all Bayesian models used in the study. It includes the minimum and maximum R̂ values for each model across both cohorts and outcome types (PCS and MCS). All R̂ values are close to 1, indicating excellent convergence of the Markov chains.
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table 3 presents the R-hat convergence diagnostics for all Bayesian models used in the study. It includes the minimum and maximum R̂ values for each model across both cohorts and outcome types (PCS and MCS). All R̂ values are close to 1, indicating excellent convergence of the Markov chains.
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Figure 3 shows posterior predictive checks for the model predicting MCS change from diagnosis to two years. The figure includes kernel density overlays and distributions of replicated vs observed means and variances.
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Figure 3 shows posterior predictive checks for the model predicting MCS change from diagnosis to two years. The figure includes kernel density overlays and distributions of replicated vs observed means and variances.
- Open Access
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table 1 presents the Bayesian model estimates of changes in physical component scores (PCS) from baseline to diagnosis and from diagnosis to two years, stratified by baseline characteristics. Values include posterior means, 95% credible intervals, and probability of direction (PD) relative to the minimally clinically important difference (MCID) thresholds.
- 9 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Predicting Health-Related Quality of Life Trajectories in Elderly Patients with Breast Cancer: From Prediagnosis to Long-term Follow-up
Supplementary Table 1 presents the Bayesian model estimates of changes in physical component scores (PCS) from baseline to diagnosis and from diagnosis to two years, stratified by baseline characteristics. Values include posterior means, 95% credible intervals, and probability of direction (PD) relative to the minimally clinically important difference (MCID) thresholds.
- Open Access
- 4 November 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (21) , e71346
Comprehensive Analysis of Genomic Variations in Pancreatic Adenocarcinoma by Race
Purpose: Racial disparities in pancreatic ductal adenocarcinoma (PDAC) incidence and outcomes persist even after adjusting for access to care and treatment received, suggesting a role for tumor‐specific molecular factors. This study aimed to compare the mutational landscape of PDAC tumor samples across racial groups using a large, diverse patient cohort. Methods: Genetic variations were analyzed using data from the AACR Project GENIE registry. Adult patients with PDAC treated at Memorial Sloan Kettering Cancer Center or Dana‐Farber Cancer Institute who underwent next‐generation sequencing were included. Somatic mutations in 680 genes were compared among White, Black, and Asian patients, controlling for multiple comparisons. Results: Among 4327 patients (mean age 66.4 years, 53% male), 61% had localized disease, while 39% had metastatic disease. The most commonly mutated genes were KRAS, TP53, SMAD4, ARID1A, KMT2D, RNF43, CDKN2A, and COL7A1. The median number of mutations per patient was 4, irrespective of race ( p ‐value = 0.45). Asian patients had significantly fewer CDKN2A mutations than White patients (0.7% vs. 9.1%, p = 1.9 × 10 −5 ) and Black patients (0.7% vs. 8.1%, p = 7.4 × 10 −4 ) as well as fewer cell‐cycle‐related mutations (4.4% vs. 11.5% and 13.0%, respectively; p = 0.012). No significant racial differences were observed in tumor mutational burden (TMB), microsatellite instability, or clinically targetable mutations ( p ‐values > 0.05). Conclusions: Asian patients with PDAC had fewer CDKN2A mutations, a genotype linked to improved survival and reduced tumor aggressiveness. Genomic profiles were otherwise similar across races, suggesting that disparities are likely driven by non‐genomic factors beyond DNA sequence alterations, such as epigenetic modifications or posttranslational changes. Integrating multiomic and clinical data is crucial to better understand and address these disparities.
- 4 November 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (21) , e71346
Open AccessComprehensive Analysis of Genomic Variations in Pancreatic Adenocarcinoma by Race
Purpose: Racial disparities in pancreatic ductal adenocarcinoma (PDAC) incidence and outcomes persist even after adjusting for access to care and treatment received, suggesting a role for tumor‐specific molecular factors. This study aimed to compare the mutational landscape of PDAC tumor samples across racial groups using a large, diverse patient cohort. Methods: Genetic variations were analyzed using data from the AACR Project GENIE registry. Adult patients with PDAC treated at Memorial Sloan Kettering Cancer Center or Dana‐Farber Cancer Institute who underwent next‐generation sequencing were included. Somatic mutations in 680 genes were compared among White, Black, and Asian patients, controlling for multiple comparisons. Results: Among 4327 patients (mean age 66.4 years, 53% male), 61% had localized disease, while 39% had metastatic disease. The most commonly mutated genes were KRAS, TP53, SMAD4, ARID1A, KMT2D, RNF43, CDKN2A, and COL7A1. The median number of mutations per patient was 4, irrespective of race ( p ‐value = 0.45). Asian patients had significantly fewer CDKN2A mutations than White patients (0.7% vs. 9.1%, p = 1.9 × 10 −5 ) and Black patients (0.7% vs. 8.1%, p = 7.4 × 10 −4 ) as well as fewer cell‐cycle‐related mutations (4.4% vs. 11.5% and 13.0%, respectively; p = 0.012). No significant racial differences were observed in tumor mutational burden (TMB), microsatellite instability, or clinically targetable mutations ( p ‐values > 0.05). Conclusions: Asian patients with PDAC had fewer CDKN2A mutations, a genotype linked to improved survival and reduced tumor aggressiveness. Genomic profiles were otherwise similar across races, suggesting that disparities are likely driven by non‐genomic factors beyond DNA sequence alterations, such as epigenetic modifications or posttranslational changes. Integrating multiomic and clinical data is crucial to better understand and address these disparities.